数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Frontotemporal lobar degeneration with tauopathy (FTLD-tau) typically manifests as either behavioral variant frontotemporal dementia (bvFTD) or primary progressive aphasia (PPA).
方法
We examined 47 autopsy-confirmed FTLD-tau cases from the Northwestern Alzheimer's Disease Research Center Brain Bank using postmortem digital pathology analysis to quantify tau phosphorylation and HLA-DR immunoreactivity in the amygdala.；In a subset of 19 PiD cases (10 bvFTD-PiD, 9 PPA-PiD), we assessed neuropsychiatric symptoms, tracked longitudinally using the Neuropsychiatric Inventory-Questionnaire (NPI-Q), and quantified neuronal and Pick body densities via unbiased stereology and neuronal sizes via digital pathology analysis.；Across the FTLD-tau cohort, bvFTD exhibited greater amygdalar neuroinflammation than PPA, despite comparable tau burden.
核心结论
FTLD-tau preferentially targets frontal and anterior temporal lobes, including the amygdala, contributing to severe neuropsychiatric symptoms.；This study investigated whether bvFTD and PPA due to FTLD-tau exhibit distinct amygdalar histopathology and whether these patterns reflect their initially distinct clinical phenotypes, particularly in PiD.；In a subset of 19 PiD cases (10 bvFTD-PiD, 9 PPA-PiD), we assessed neuropsychiatric symptoms, tracked longitudinally using the Neuropsychiatric Inventory-Questionnaire (NPI-Q), and quantified neuronal and Pick body densities via unbiased stereology and neuronal sizes via digital pathology analysis. ‖ 结论：These findings underscore the potential role of neuroinflammation in shaping clinical phenotypes in FTLD and highlight the role of the amygdala in complex clinicopathologic relationships.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
原文题录
- 英文标题：Amygdala vulnerability in Pick disease with discrete frontotemporal dementia syndromes.
- 期刊与标识：Brain Pathol · PMID 42945950 · DOI 10.1111/bpa.70159**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。